Copyright 2018 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25.68% per year. These returns cover a period from January 1, 1988 to October 1, 2018. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit performance for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
medical: Archive
Will Core Business Units Aid McKesson's (MCK) Q2 Earnings?
by Zacks Equity Research
McKesson (MCK) is expected to gain from strong segmental performances in Q2 of fiscal 2019.
MASI BIO BAX MCK
medical
Agios Rides on Tibsovo Approval Amid Reliance on Celgene
by Zacks Equity Research
Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.
AZN MRK AGIO CELG
medical
Mallinckrodt (MNK) Gets $26 Million as Funding From BARDA
by Zacks Equity Research
Mallinckrodt (MNK) gets $26 million for additional funding from BARDA for pediatric studies of StrataGraft skin tissue in thermal burns.
BAX MDCO MNK MYL
medical
LabCorp (LH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
LabCorp (LH) might sustain its winning streak in third-quarter 2018 after having retained the same for the past few quarters. However, reimbursement pressure remains a concern.
MASI DVA HSIC LH
earnings medical
Can Overall Growth Drive Thermo Fisher (TMO) Q3 Earnings?
by Zacks Equity Research
Thermo Fisher's (TMO) steadily strong analytical instrument business flaunts higher global demand.
TMO MASI DVA HSIC
earnings medical
Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Strong performance in the Instruments & Accessories and Systems segments drive Intuitive Surgical's (ISRG) top line in Q3.
INGN ISRG BAX EW
earnings medical
Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch
by Ryan McQueeney
Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.
JNJ CHCT
finance medical
Trump vs. The Fed and PayPal, Intuitive Surgical Earnings Previews
by Ryan McQueeney
Ryan McQueeney discusses the Fed's decision to remain hawkish amid criticism from President Trump. He also recaps earnings results from Travelers, Blackstone, and Philip Morris. Later, he is joined by Dave Bartosiak to preview upcoming reports from PayPal and Intuitive Surgical.
PYPL BX TRV ISRG PM
earnings medical tech-stocks
Top-Ranked Healthcare ETFs for Long-Term Investors
by Neena Mishra
Healthcare is now the best-performing sector of 2018. We highlight two top-ranked ETFs suitable for long-term investors.
PFE JNJ XLV VHT UNH
etfs medical
This Week's Hottest Earnings Charts
by Tracey Ryniec
Wall Street will be tuning into the earnings reports on these 5 companies this week.
PYPL CE ISRG SKX OZK
earnings finance medical retail
Bio-Techne Partners Micropoint Bioscience, Expands in China
by Zacks Equity Research
Bio-Techne (TECH) believes that its Chinese collaboration is a strategic fit as it will solidify the integration of microfluidic technology for more apt POC diagnostic tools for precision medicine.
MRK TECH BIO
medical
Will Edwards' (EW) Steady Overall Growth Drive Q3 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q3.
TMO BAX EW MYGN
medical
Can Overall Growth Drive Align Technology (ALGN) Q3 Earnings?
by Zacks Equity Research
Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q3.
TMO BAX MYGN ALGN
medical
Top Analyst Reports for AstraZeneca, Salesforce & Mastercard
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca (AZN), salesforce.com (CRM) and Mastercard (MA)
PHG MA LRCX E CRM AZN
business-services computers medical
Will Boston Scientific's (BSX) Q3 Earnings Reflect Overall Gain?
by Zacks Equity Research
We are optimistic about the IC business that will help Boston Scientific (BSX) maintain impressive global growth, owing to an innovative portfolio and robust commercial teams.
MASI BSX DVA HSIC
earnings medical
Will 5 Elements Drive Quest Diagnostics (DGX) Q3 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) growing partnerships with health care leaders and strategic acquisitions are expected to boost top and bottom-line growth in Q3.
TMO BAX MYGN DGX
medical
Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed
by Zacks Equity Research
Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.
ABT INGN EW BAX
earnings medical
Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings?
by Zacks Equity Research
Illumina (ILMN) is likely to gain from strong revenues at the Product, Service and other segments in Q3.
TMO BAX MYGN ILMN
medical
This Week's Most Spectacular Earnings Charts
by Tracey Ryniec
It doesn't get much better than these five big cap companies with their outstanding earnings surprise records and great earnings charts.
NFLX JNJ UNH DPZ LRCX
consumer-discretionary earnings insurance medical restaurants
Acadia Healthcare (ACHC) Surges: Stock Moves 7.9% Higher
by Zacks Equity Research
Acadia Healthcare (ACHC) shares rose nearly 8% in the last trading session, amid huge volumes.
LPNT ACHC
medical
Roche Announces Positive Data on Breast Cancer Drug Kadcyla
by Zacks Equity Research
Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal.
RHHBY NVS AMGN IMGN
medical
EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
VBLT EYPT
medical
Implied Volatility Surging for Akorn (AKRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.
AKRX
medical
Company News For Oct 16, 2018
by Zacks Equity Research
Companies In The News are: JBHT,HRS,SCHW,CGC
JBHT HRS SCHW CGC
computers finance medical transportation
Will Optum Aid UnitedHealth Group's (UNH) Q3 Earnings?
by Zacks Equity Research
Revenue and earnings gains across all the Optum's subsegments should aid UnitedHealth's Q3 earnings.
CI AET MOH UNH
medical